SFU
ANIP icon

Stonehage Fleming (UK)’s ANI Pharmaceuticals ANIP Stock Holding History

Stonehage Fleming (UK)’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-413
Closed -$12K – 298
2014
Q3 		$12K Sell
413
-436
-51% -$13.1K 0.01% 290
2014
Q2 		$29K Buy
+849
New +$26.6K 0.01% 215

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
FIM
Foresters Investment Management New York $5.05B AUM 5.06% 1-Year Est. Return

Stonehage Fleming (UK)'s ANIP Position: Q4 2014 in Review

Stonehage Fleming (UK) sold out of ANI Pharmaceuticals (ANIP) in Q4 2014, closing a stake of 413 shares — an estimated $12K sold.

Stonehage Fleming (UK) first reported a position in ANIP in Q2 2014 and held it in 2 quarters. The position peaked at $29K in Q2 2014. 101 funds tracked by Wall St. Rank hold ANIP as of Q4 2014.

  • Stonehage Fleming (UK) reported no remaining ANI Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Stonehage Fleming (UK) sold 413 ANI Pharmaceuticals shares in Q4 2014, an estimated $12K.
  • Stonehage Fleming (UK) first reported a position in ANI Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Stonehage Fleming (UK)'s ANI Pharmaceuticals position peaked at $29K in Q2 2014.
  • 101 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2014.

Based on Stonehage Fleming (UK)'s 13F filing for Q4 2014, filed 11 Oct 2019.